Wu Liping, Liu Junjie, Chang Xiaoke, Zheng Yijun
Department of Glaucoma and Cataract, Aier Eye Hospital Group Hankou Hospital of Wuhan Aier Eye Hospital Wuhan, Hubei, China.
Department of Fundas, Aier Eye Hospital Group Hankou Hospital of Wuhan Aier Eye Hospital Wuhan, Hubei, China.
Am J Transl Res. 2021 Aug 15;13(8):9729-9735. eCollection 2021.
To explore the clinical effectiveness of Healaflow in primary angle-closure glaucoma surgery.
From August 2018 to July 2019, 100 primary angle-closure glaucoma patients admitted to our ophthalmology department were divided into a control group (trabeculectomy alone) and an observation group (trabeculectomy + Halver), with 50 patients in each group, and 53 eyes in the control group and 56 eyes in the observation group. All the patients were followed up for half a year. The vision, intraocular pressure, bleb morphology, efficacy, and adverse reactions were evaluated.
There was no significant difference in the visual acuity between the two groups of patients during the follow-up (P > 0.05). The intraocular pressure levels in the two groups of patients during the follow-up were significantly lower than they were before the treatment (P < 0.05), and the difference in the intraocular pressure levels between the 6th month postoperative groups was significant (P < 0.05). During the last follow-up, 45 eyes in the control group developed functional filtration blebs, and 8 eyes had non-functioning filtration blebs. There were 55 functional filtration blebs and 1 non-functional filtration bleb in the observation group ( = 4.731, P = 0.030). The total effective rate in the observation group was higher than it was in the control group (92.86% VS 77.36%, = 4.058, P = 0.044). During the follow-up period, the control group had 2 eyes with anterior chambers, 1 eye with low intraocular pressure, and 1 eye with an iris adhesion. The observation group had 1 eye with an anterior chamber, and no significant difference in the complications between the groups was evident (P > 0.05).
Healaflow is of great value in maintaining functional filtration blebs and in controlling and stabilizing intraocular pressure. It is safe and reliable in clinical application, and it helps to reduce the unstable intraocular pressure after glaucoma surgery caused by scar adhesions in the filtration channel.
探讨Healaflow在原发性闭角型青光眼手术中的临床疗效。
选取2018年8月至2019年7月我院眼科收治的100例原发性闭角型青光眼患者,分为对照组(单纯小梁切除术)和观察组(小梁切除术+Healaflow),每组50例,对照组53眼,观察组56眼。所有患者均随访半年,评估视力、眼压、滤过泡形态、疗效及不良反应。
随访期间两组患者视力比较,差异无统计学意义(P>0.05)。两组患者随访期间眼压水平均显著低于治疗前(P<0.05),术后6个月两组眼压水平差异有统计学意义(P<0.05)。末次随访时,对照组45眼形成功能性滤过泡,8眼形成非功能性滤过泡。观察组有55眼形成功能性滤过泡,1眼形成非功能性滤过泡(χ²=4.731,P=0.030)。观察组总有效率高于对照组(92.86%比77.36%,χ²=4.058,P=0.044)。随访期间,对照组有2眼前房形成、1眼低眼压、1眼虹膜粘连。观察组有1眼前房形成,两组并发症差异无统计学意义(P>0.05)。
Healaflow在维持功能性滤过泡及控制和稳定眼压方面具有重要价值,临床应用安全可靠,有助于减少青光眼手术后因滤过通道瘢痕粘连导致的眼压不稳定。